Compare Howmet Aerospace Inc (HWM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Recursion Pharmaceuticals Inc — how do they compare? Howmet Aerospace Inc trades at $224.63 (market cap $88.76B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Howmet Aerospace Inc is far larger — about 41.5× Recursion Pharmaceuticals Inc's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| HWM | RXRX | |
|---|---|---|
Market Cap | $88.76B | $2.14B |
Volume | 2,648,516 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $292.65 | $6.79 |
52-Week Low | $184.09 | $2.84 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $92.86B | $1.66B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.55, up 1.28% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income are projected to grow in 2026, supported by robust demand in aerospace and defense. Analyst consensus is overwhelmingly bullish, with an 84% buy rating and a $328.10 price target, indicating significant upside potential from current levels.
The outlook for HWM is positive, driven by earnings growth and sector tailwinds, though technical indicators suggest near-term caution. Key risks include supply-chain pressures and competitive dynamics. Institutional interest remains strong, supporting the long-term investment case for shareholders focused on aerospace exposure.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
